Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 5/2012

01-10-2012 | Research Article

Expression of transforming growth factor-β1 (TGF-β1) and E-cadherin in glioma

Authors: Liu Yang, Mei Liu, Chuanzong Deng, Zhikai Gu, Yilu Gao

Published in: Tumor Biology | Issue 5/2012

Login to get access

Abstract

Gliomas are the most common tumors in the central nervous system. This study aims to investigate the expressions of transforming growth factor-β1 (TGF-β1) and epithelial cadherin (E-cadherin) in human brain glioma tissues and the correlation between their expressions with clinical pathological features and clinical significance. The expressions of mRNA or protein of TGF-β1 and E-cadherin were detected by using reverse transcription polymerase chain reaction (RT-PCR) and Western blot in these tissues. Positive rates of the expression of TGF-β1 and E-cadherin were 62.9 % and 38.6 % in brain tissues of glioma patients. The expressions of mRNA or protein for TGF-β1 in brain glioma tissues were significantly higher than that in normal brain tissues (p < 0.01). Their expressions in well-differentiated glioma brain tissues were lower than those in poorly differentiated glioma brain tissues (p < 0.01). A negative correlation was found between TGF-β1 and E-cadherin in brain glioma tissues (r = −0.302, p < 0.011). The cell numbers of C6 glioma through Transwell chambers were decreased significantly (p < 0.01), and the expression of TGF-β1 was downregulated significantly (p < 0.01). However, the expression of E-cadherin was upregulated significantly (p < 0.01) after transfecting TGF-β1 siRNA. The expression changes of TGF-β1 and E-cadherin may be related to the emergence and the development of glioma. Downregulation of TGF-β1 expression using siRNA can decrease the invasive capability of C6 glioma cells.
Literature
1.
Iwami K, Natsume A, Wakabayashi T. Cytokine networks in glioma. Neurosurg Rev. 2011;34(3):253–63.CrossRefPubMed
2.
Rainov NG, Heidecke V. Clinical development of experimental therapies for malignant glioma. Sultan Qaboos Univ Med J. 2011;11(1):5–28.PubMedPubMedCentral
3.
Kros JM. Grading of gliomas: the road from eminence to evidence. J Neuropathol Exp Neurol. 2011;70(2):101–9.CrossRefPubMed
4.
Sasine JP, Savaraj N, Feun LG. Topoisomerase I inhibitors in the treatment of primary CNS malignancies: an update on recent trends. Anticancer Agents Med Chem. 2010;10(9):683–96.CrossRefPubMed
5.
Strik HM, Kolodziej M, Oertel W, Basecke J. Glycobiology in malignant gliomas: expression and functions of galectins and possible therapeutic options. Curr Pharm Biotechnol 2011.
6.
Hdeib A, Sloan AE. Convection-enhanced delivery of (131)I-chTNT-1/B mAB for treatment of high-grade adult gliomas. Expert Opin Biol Ther. 2011;11(6):799–806.CrossRefPubMed
7.
8.
Plaas A, Velasco J, Gorski DJ, Li J, Cole A, Christopherson K, Sandy JD. The relationship between fibrogenic TGFbeta1 signaling in the joint and cartilage degradation in post-injury osteoarthritis. Osteoarthritis Cartilage 2011.
9.
Yang SY, Miah A, Pabari A, Winslet M. Growth factors and their receptors in cancer metastases. Front Biosci. 2011;16:531–8.CrossRef
10.
Pardali E, ten Dijke P. Transforming growth factor-beta signaling and tumor angiogenesis. Front Biosci. 2009;14:4848–61.CrossRef
11.
Hinck AP, O'Connor-McCourt MD. Structures of TGF-beta receptor complexes: implications for function and therapeutic intervention using ligand traps. Curr Pharm Biotechnol 2011.
12.
Hau P, Jachimczak P, Schlaier J, Bogdahn U. TGF-beta2 signaling in high-grade gliomas. Curr Pharm Biotechnol 2011.
13.
Di C, Mattox AK, Harward S, Adamson C. Emerging therapeutic targets and agents for glioblastoma migrating cells. Anticancer Agents Med Chem. 2011;10(7):543–55.CrossRef
14.
You S, Alyanakian MA, Segovia B, Damotte D, Bluestone J, Bach JF, Chatenoud L. Immunoregulatory pathways controlling progression of autoimmunity in NOD mice. Ann N Y Acad Sci. 2008;1150:300–10.CrossRefPubMedPubMedCentral
15.
Cavallaro U, Dejana E. Adhesion molecule signalling: not always a sticky business. Nat Rev Mol Cell Biol. 2011;12(3):189–97.CrossRefPubMed
16.
17.
Pan J, Yang M. The role of epithelial–mesenchymal transition in pancreatic cancer. J Gastrointest Oncol. 2011;2(3):151–6.PubMedPubMedCentral
18.
19.
Herfs M, Hubert P, Kholod N, Caberg JH, Gilles C, Berx G, Savagner P, Boniver J, Delvenne P. Transforming growth factor-beta1-mediated Slug and Snail transcription factor up-regulation reduces the density of Langerhans cells in epithelial metaplasia by affecting E-cadherin expression. Am J Pathol. 2008;172(5):1391–402.CrossRefPubMedPubMedCentral
20.
Chamberlain MC. Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas. Expert Rev Neurother. 2010;10(10):1537–44.CrossRefPubMed
21.
Schiffer D, Annovazzi L, Caldera V, Mellai M. On the origin and growth of gliomas. Anticancer Res. 2010;30(6):1977–98.PubMed
22.
Sciume G, Santoni A, Bernardini G. Chemokines and glioma: invasion and more. J Neuroimmunol. 2010;224(1–2):8–12.CrossRefPubMed
23.
Sherman JH, Hoes K, Marcus J, Komotar RJ, Brennan CW, Gutin PH. Neurosurgery for brain tumors: update on recent technical advances. Curr Neurol Neurosci Rep. 2011;11(3):313–9.CrossRefPubMed
24.
Prager GW, Poettler M, Unseld M, Zielinski CC. Angiogenesis in cancer: anti-VEGF escape mechanisms. Transl Lung Cancer Res. 2012;1(1):14–25.PubMedPubMedCentral
25.
Candolfi M, Kroeger KM, Muhammad AK, Yagiz K, Farrokhi C, Pechnick RN, Lowenstein PR, Castro MG. Gene therapy for brain cancer: combination therapies provide enhanced efficacy and safety. Curr Gene Ther. 2009;9(5):409–21.CrossRefPubMedPubMedCentral
26.
Schor AM, Schor SL. Angiogenesis and tumour progression: migration-stimulating factor as a novel target for clinical intervention. Eye (Lond). 2010;24(3):450–8.CrossRef
27.
Glick AB, Perez-Lorenzo R, Mohammed J. Context-dependent regulation of cutaneous immunological responses by TGFbeta1 and its role in skin carcinogenesis. Carcinogenesis. 2008;29(1):9–14.CrossRefPubMed
28.
Li AG, Lu SL, Han G, Kulesz-Martin M, Wang XJ. Current view of the role of transforming growth factor beta 1 in skin carcinogenesis. J Investig Dermatol Symp Proc. 2005;10(2):110–7.CrossRefPubMed
29.
Soufla G, Sifakis S, Baritaki S, Zafiropoulos A, Koumantakis E, Spandidos DA. VEGF, FGF2, TGFB1 and TGFBR1 mRNA expression levels correlate with the malignant transformation of the uterine cervix. Cancer Lett. 2005;221(1):105–18.CrossRefPubMed
30.
Johnson C, Han YY, Nathan H, McCarra J, Alpini G, Meng F. Interleukin-6 and its receptor, key players in hepatobiliary inflammation and cancer. Transl Gastrointest Cancer. 2012;1(1):58–70.PubMedPubMedCentral
31.
Bellone G, Carbone A, Tibaudi D, Mauri F, Ferrero I, Smirne C, Suman F, Rivetti C, Migliaretti G, Camandona M, et al. Differential expression of transforming growth factors-beta1, -beta2 and -beta3 in human colon carcinoma. Eur J Cancer. 2001;37(2):224–33.CrossRefPubMed
32.
Djaborkhel R, Tvrdik D, Eckschlager T, Raska I, Muller J. Cyclin A down-regulation in TGFbeta1-arrested follicular lymphoma cells. Exp Cell Res. 2000;261(1):250–9.CrossRefPubMed
33.
Shariat SF, Kim JH, Andrews B, Kattan MW, Wheeler TM, Kim IY, Lerner SP, Slawin KM. Preoperative plasma levels of transforming growth factor beta(1) strongly predict clinical outcome in patients with bladder carcinoma. Cancer. 2001;92(12):2985–92.CrossRefPubMed
34.
Sulzer MA, Leers MP, van Noord JA, Bollen EC, Theunissen PH. Reduced E-cadherin expression is associated with increased lymph node metastasis and unfavorable prognosis in non-small cell lung cancer. Am J Respir Crit Care Med. 1998;157(4 Pt 1):1319–23.CrossRefPubMed
35.
Zigler M, Dobroff AS, Bar-Eli M. Cell adhesion: implication in tumor progression. Minerva Med. 2010;101(3):149–62.PubMed
36.
Mikheeva SA, Mikheev AM, Petit A, Beyer R, Oxford RG, Khorasani L, Maxwell JP, Glackin CA, Wakimoto H, Gonzalez-Herrero I, et al. TWIST1 promotes invasion through mesenchymal change in human glioblastoma. Mol Cancer. 2010;9:194.CrossRefPubMedPubMedCentral
37.
Hills CE, Squires PE. TGF-beta1-induced epithelial-to-mesenchymal transition and therapeutic intervention in diabetic nephropathy. Am J Nephrol. 2010;31(1):68–74.CrossRefPubMed
38.
Nakajima S, Doi R, Toyoda E, Tsuji S, Wada M, Koizumi M, Tulachan SS, Ito D, Kami K, Mori T, et al. N-cadherin expression and epithelial–mesenchymal transition in pancreatic carcinoma. Clin Cancer Res. 2004;10(12 Pt 1):4125–33.CrossRefPubMed
39.
Takano S, Kanai F, Jazag A, Ijichi H, Yao J, Ogawa H, Enomoto N, Omata M, Nakao A. Smad4 is essential for down-regulation of E-cadherin induced by TGF-beta in pancreatic cancer cell line PANC-1. J Biochem. 2007;141(3):345–51.CrossRefPubMed
Metadata
Title
Expression of transforming growth factor-β1 (TGF-β1) and E-cadherin in glioma
Authors
Liu Yang
Mei Liu
Chuanzong Deng
Zhikai Gu
Yilu Gao
Publication date
01-10-2012
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 5/2012
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-012-0398-z

Other articles of this Issue 5/2012

Tumor Biology 5/2012 Go to the issue

Research Article

Expression and association of HER2 with prognosis in early-stage (T1–T2N0M0) non-small cell lung cancer

Research Article

Diagnostic accuracy of tumour markers in serous effusions: a validation study

Research Article

Discriminant analysis involving serum cytokine levels and prediction of the response to therapy of patients with Hodgkin lymphoma

Research Article

EphB4 is overexpressed in papillary thyroid carcinoma and promotes the migration of papillary thyroid cancer cells

Research Article

Association between EGF +61 genetic polymorphisms and non-small cell lung cancer increased risk in a Portuguese population: a case–control study

Research Article

RIN1 exhibits oncogenic property to suppress apoptosis and its aberrant accumulation associates with poor prognosis in melanoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits